论文部分内容阅读
从１９９５年６月至１９９６年２月，我们用解放军３０２医院华星制药厂生产的膦甲酸注射液治疗了２１例慢性乙型及／或丙型肝炎患者，以评价该药对乙、丙型肝炎的临床抗病毒疗效及不良反应。其中１４例单纯乙型，３例乙、丙型重叠感染，４例单纯丙型。治疗方法为２５００ｍｇ静滴（２ｈ输完）ｑ１２ｈ，疗程２８ｄ。结果：治疗前ＨＢｓＡｇ（＋）１７例，ＨＢｅＡｇ（＋）１２例，ＨＢＶＤＮＡ（＋）１３例，治疗结束时ＨＢｓＡｇ、ＨＢｅＡｇ及ＨＢＶＤＮＡ分别有１例（５．９％）、７例（５８．３％）及１０例（７６．９％）转阴。治疗前抗－ＨＣＶ（＋）５例，ＨＣＶＲＮＡ（＋）７例，治疗结束时抗－ＨＣＶ及ＨＣＶＲＮＡ分别有１例（２０．０％）及４例（５７．１％）转阴，另有２例用药后血清ＨＣＶＲＮＡ浓度下降约９０％。不良反应大多较轻，发生率为４２．９％，主要为纳差、恶心、腹胀、乏力等消化道及全身症状。３例血钾轻至中度降低，仅１例因恶心、呕吐较重于用药第１７天停药。本研究结果提示，按本文给药方法静点膦甲酸可以达到较好的抑制乙肝病毒复制的效果，对丙肝病毒复制很可能也有抑制作用。
From June 1995 to February 1996, we treated 21 patients with chronic hepatitis B and / or C with foscarnet injection produced by Huaxing Pharmaceutical Factory, 302 Hospital of People’s Liberation Army to evaluate the efficacy of this drug in hepatitis B and C The clinical anti-virus efficacy and adverse reactions. Of which 14 cases of simple B, 3 cases of B, C overlapping infection, 4 cases of simple C-type. Treatment for intravenous infusion of 2500mg (2h lost) q12h, treatment 28d. Results: There were 17 cases of HBsAg (+) before treatment, 12 cases of HBeAg (+) and 13 cases of HBVDNA (+). At the end of treatment, HBsAg, HBeAg and HBVDNA were found in 1 case %) And 10 cases (76.9%) turned negative. There were 5 cases of anti-HCV (+) and 7 cases of HCVRNA (+) before treatment. One case (20.0%) and 4 cases (57.1%) of anti-HCV and HCV RNA were negative at the end of treatment, Two cases of serum HCVRNA concentration decreased by about 90%. Adverse reactions are mostly mild, the incidence was 42.9%, mainly anorexia, nausea, bloating, fatigue and other gastrointestinal and systemic symptoms. 3 cases of serum potassium decreased slightly to mild, only 1 case of nausea, vomiting heavier on the first 17 days of drug withdrawal. The results suggest that, according to the method of administration of static point foscarnet can achieve better inhibition of hepatitis B virus replication, hepatitis C virus replication is likely to also have inhibitory effect.